Related by context. All words. (Click for frequent words.) 69 serum HCV RNA 66 timepoint 66 undetectable HBV DNA 66 virological response 66 virologic response 66 cEVR 65 DAS# CRP 65 HBeAg seroconversion 65 mg/m2 dose 65 null responders 65 undetectable HCV RNA 64 plasma HCV RNA 64 sustained virological response 64 rapid virologic response 64 dose cohort 64 HBV DNA 64 Crohn Disease Activity 64 undetectable hepatitis C 64 null responder HCV 63 evaluable subjects 63 atazanavir ritonavir 63 ug dose 63 detectable HCV RNA 63 undetectable viral load 63 BARACLUDE ® 63 sustained virologic response 63 virologic failure 63 relapsed MM 63 log# reduction 63 CDAI 63 biochemical relapse 63 genotypic resistance 62 remission CR 62 certolizumab 62 achieved ACR# 62 ribavirin therapy 62 KRAS mutations occur 62 HBeAg 62 HCV RNA 62 SVR# 62 μg dose 62 moderately emetogenic 62 experienced virologic failure 61 CRp 61 complete cytogenetic response 61 PASI scores 61 clodronate 61 hepatitis C genotype 61 HBeAg positive patients 61 HSCT 61 CCyR 61 ACR# response 61 HBeAg negative patients 61 dosing cohort 61 IU mL 61 HBeAg negative 61 Pegasys plus Copegus 61 baseline LDH 61 timepoints 60 leukemia AML 60 virologic breakthrough 60 tipranavir r 60 MCyR 60 alanine aminotransferase ALT 60 mcg BID 60 evaluable patients 60 treatment naive genotype 60 HIV RNA 60 interferon ribavirin 60 APTIVUS r 60 CIMZIA ™ 60 pT2 60 SCIg 60 CR nPR 60 stage IIIB 60 clinically meaningful improvement 60 plus methotrexate 60 undetectable viral 60 HCV viral 60 glycated hemoglobin levels 60 null responder 60 serum HBV DNA 60 CIMZIA TM 59 viral titers 59 prior chemotherapy regimens 59 Rapid Virologic Response 59 log# copies mL 59 lamivudine refractory patients 59 mcg albinterferon alfa 2b 59 oxycodone CR 59 oral allopurinol 59 TMC# r 59 virological suppression 59 mg kg dose 59 efavirenz EFV 59 virologic suppression 59 pCR 59 randomized multicenter trial 59 hours postdose 59 HBV DNA levels 59 RRMS patients 59 HBeAg positive 59 8mg/kg 59 PSA nadir 59 octreotide LAR 59 TPV r 59 copies mL 59 dose cohorts 59 cytogenetic response 59 pegylated interferon alpha 59 ALT flares 59 oblimersen 59 posttreatment 59 CLL SLL 59 pT3 59 binary restenosis 59 doxorubicin docetaxel 59 RESIST studies 59 EDSS score 59 Index CDAI 59 highly emetogenic 59 metastatic CRC 59 phase IIb study 59 ALT normalization 59 CDAI score 59 mg QD 59 Flu Cy 59 PEG IFN 59 4mg/kg 59 Virologic 59 recurrent glioblastoma multiforme 59 dosing cohorts 58 genotype 1b 58 phase IIb trial 58 Viral load 58 ipsilateral stroke 58 radical prostatectomy RP 58 ritonavir boosted 58 NIH CPSI 58 CCR5 tropic HIV 58 ribavirin RBV 58 FOLFOX6 58 small lymphocytic lymphoma 58 severe neutropenia 58 lopinavir r arm 58 severe exacerbations 58 #mg/m# [001] 58 XIENCE V PROMUS Stent 58 prospectively defined 58 mRCC 58 liver histology 58 undetectable viral loads 58 piperacillin tazobactam 58 CIMZIA TM certolizumab pegol 58 #mg BID [001] 58 endoscopic remission 58 gemcitabine carboplatin 58 receiving highly emetogenic 58 CIN3 58 invasive aspergillosis 58 ertapenem 58 tipranavir ritonavir 58 partial remissions 58 PREZISTA r 58 ascending dose 58 #mg/day [001] 58 crizotinib PF # 58 % CI #.#-#.# [003] 58 HCV Genotype 58 posaconazole 58 IELT 58 mg BID 58 budesonide foam 58 copies ml 58 autologous SCT 58 Darusentan 58 T2 lesions 58 virologic 58 apremilast 57 median CD4 57 peginterferon alfa 2a 57 q#d 57 ancrod 57 -#.# log# 57 lamivudine monotherapy 57 flutamide 57 EDSS scores 57 Cimzia TM 57 #mg QD [002] 57 cytogenetic responses 57 anagrelide 57 ruboxistaurin 57 tumor histology 57 NRTI resistance 57 LEXIVA r 57 HbA 1c levels 57 NMIBC 57 chlorambucil 57 nonmetastatic prostate cancer 57 VELCADE melphalan 57 biochemical recurrence 57 complete cytogenetic 57 rFSH 57 mucosal healing 57 mcg kg 57 seropositive patients 57 corticosteroid dose 57 achieved CCyR 57 ibandronate 57 cell lymphoma CTCL 57 HCV SPRINT 57 remission induction 57 symptomatic BPH 57 Ishak fibrosis score 57 FluCAM 57 lymphocytosis 57 MAGE A3 ASCI 57 inhibitor RG# 57 HCV genotype 1 57 mCRPC 57 heavily pretreated 57 seroconversion 57 relapsed AML 57 IU ml 57 Solid Tumors criteria 57 treatment naïve genotype 57 cytoreduction 57 virological failure 57 eculizumab therapy 57 peginterferon alfa 2b 57 relapsed GBM 57 Betaferon ® 57 resected pancreatic cancer 57 Virologic failure 57 Hb A1C 57 metastatic renal cell carcinoma 57 cART 57 HCV RESPOND 2 57 Helicobacter pylori eradication 57 plus dexamethasone 57 refractory AML 57 viral kinetics 57 nab paclitaxel 57 forodesine 57 receiving VICTRELIS 57 mg/m2 IV 57 recurrent genital herpes 57 COPD exacerbation 57 relapsed refractory multiple myeloma 57 serum testosterone 57 desvenlafaxine succinate 57 FluCAM arm 57 standard chemotherapy regimen 57 ACR# responses 57 protease inhibitor PI 57 peginterferon alfa 2a #KD 57 antiangiogenic therapy 57 plus gemcitabine 57 Hycamtin ® 57 caspofungin 57 metastatic hormone refractory 57 neoadjuvant chemotherapy 57 ritonavir boosted lopinavir 57 definite stent thrombosis 57 nucleoside naive 57 Kaplan Meier estimate 57 interquartile range 57 subanalysis 57 DAS# remission 57 postintervention 57 LPV r 57 microbiological eradication 57 systemic ALCL 57 response pCR 57 seroconverted 56 tipranavir 56 viral load 56 nadroparin 56 macroalbuminuria 56 biliary tract cancer 56 trastuzumab Herceptin ® 56 tapentadol ER 56 Engerix B 56 peginterferon 56 Phase #/#a 56 QD dosing 56 lumbar spine BMD 56 refractory CLL 56 annualized relapse 56 p = #.# [003] 56 estimated glomerular filtration 56 hepatocellular cancer 56 achieving PASI 56 CHOP chemotherapy 56 rizatriptan 56 cinacalcet 56 mg ustekinumab 56 histologically confirmed 56 Index CDAI score 56 FOLFIRINOX 56 Velcade bortezomib 56 amoxicillin clavulanate 56 Stage IIB 56 5-FU/LV 56 Rapid Virological Response 56 #mg q8h 56 HBeAg + 56 hepatic fibrosis 56 NATRECOR ® 56 oral methylnaltrexone 56 concurrent chemoradiation 56 q8h 56 cells mcL 56 BENICAR 56 pediatric acute lymphoblastic 56 mitoxantrone plus 56 pomalidomide 56 transaminase levels 56 Copegus ribavirin 56 stage IIIb IV 56 SUVmax 56 MADRS score 56 nucleotide analog 56 AMEVIVE 56 pooled comparator 56 Renal Cell Carcinoma RCC 56 oral vancomycin 56 Amrubicin 56 mCRC patients 56 haematologic 56 adalimumab 56 mg/m2/day 56 fosamprenavir 56 adalimumab Humira 56 receptor tyrosine kinase inhibitor 56 serum urate levels 56 interferon beta therapy 56 TEAEs 56 chronic HCV 56 alkylating agent 56 Solid Tumors RECIST 56 gastrointestinal stromal tumors GIST 56 Psoriasis Area 56 low dose cytarabine 56 SPRYCEL ® 56 leukemia ALL 56 response CCyR 56 iniparib BSI 56 doxorubicin cyclophosphamide 56 RAPTIVA 56 elotuzumab 56 HbA1c levels 56 recurrent VTE 56 JAK2 V#F 56 VFEND 56 refractory NSCLC 56 dexpramipexole 56 placebo dexamethasone 56 chemoradiation therapy 56 rapid virological response 56 pegylated interferon alfa 56 prospectively enrolled 56 ZOLINZA 56 canakinumab 56 ACTEMRA TM 56 elevated LDH 56 baseline PASI 56 peg interferon 56 serum urate 56 aspartate aminotransferase AST 56 progression TTP 56 μmol L 56 serum aminotransferase levels 56 antiretroviral naïve 56 CCR5 antagonist 56 Response Evaluation Criteria 56 histological subtype 56 plasma uric acid 56 INC# 56 debulking surgery 56 relapsing multiple sclerosis 56 castrate resistant 56 heavily pretreated patients 56 briakinumab 56 Doxil ® 56 EGFR TKI 56 FIRMAGON 56 relapsed multiple myeloma 56 Median PFS 56 intradermal injections 56 intravenous diuretics 56 MabCampath 55 antibody titer 55 seroprotection 55 receiving ISENTRESS 55 posttransplant 55 hemoglobin A1c levels 55 AGILECT R 55 steroid dexamethasone 55 radiographic progression 55 Tmax 55 lesional 55 FDA defined valvulopathy 55 colorectal adenoma 55 intermittent dosing 55 HAART regimen 55 Traficet EN 55 coinfected 55 REYATAZ R 55 GSK# [001] 55 dacarbazine chemotherapy 55 RECIST criteria 55 TDF FTC 55 bladder carcinoma 55 acromegalic patients 55 undetectable virus HCV 55 generalized edema 55 unresectable stage 55 Viread Emtriva 55 docetaxel chemotherapy 55 achieved sustained virological 55 invasive ductal 55 q#h 55 bendamustine 55 liver transplant recipients 55 rilonacept 55 underwent resection 55 ALT elevation 55 pyrazinamide 55 adefovir treated 55 underwent surgical resection 55 trials RCTs 55 daily subcutaneous injections 55 QTcF 55 active comparator 55 virologically 55 tenecteplase 55 APTIVUS R 55 IIIa inhibitors 55 PSADT 55 NIHSS 55 antigen PSA levels 55 previously untreated follicular 55 oral ridaforolimus 55 HCV infected 55 candidemia 55 Elitek 55 mg TID 55 intravenous dosing 55 mL/min/#.# m 2 55 CAELYX 55 Kaplan Meier estimates 55 specific antigen PSA 55 receiving INTRON 55 statistical significance p 55 darunavir r 55 chemoradiotherapy 55 metastatic malignant melanoma 55 mg m² 55 OGTT 55 advanced adenoma 55 elacytarabine 55 histologically proven 55 IQR 55 YMRS 55 serum concentrations 55 COMBIVIR 55 Operative mortality 55 nonsmall cell lung cancer 55 lymphopenia 55 mg qd 55 sargramostim 55 intratumoral 55 ongoing Phase 1b 55 femoral neck BMD 55 ABC/3TC 55 complete remissions 55 CANCIDAS 55 HNSCC 55 NSABP B 55 ug mL 55 baseline HbA1c 55 Peg IFN 55 mL/min/#.# m2 55 bortezomib refractory 55 FDG PET imaging 55 tumor regressions 55 ARB telmisartan 55 platinum refractory 55 nonmetastatic 55 Phase IIIb clinical 55 seropositivity 55 pegIFN 55 splenectomized patients 55 Targretin capsules 55 nucleoside naive patients 55 abacavir lamivudine 55 BENICAR HCT 55 Stage IIIb 55 RNA copies mL 55 recurrent GBM 55 rFVIIa 55 lumiliximab 55 biologic DMARD 55 mcg QD 55 antithymocyte globulin 55 inflammatory lesions 55 oral FTY# 55 Pegasys ® 55 ug kg 55 DAS# [002] 55 decitabine 55 % CI #.#-#.# [008] 55 DAPT 55 RSD# oral 55 gout flares 55 teriflunomide 55 secondary efficacy endpoints 55 Target Lesion Revascularization TLR 55 PegIntron 55 xanthine oxidase inhibitor 55 edifoligide 55 Decitabine 55 viral suppression 55 metastatic GIST 55 retrospective cohort 55 R# #mg BID 55 virologic failures 55 mg administered orally 55 huN# DM1 55 Tarceva TM 55 CR CRu 55 β blockers 55 trastuzumab DM1 55 ALT elevations 55 metastatic RCC 55 ACR Pedi 55 enfuvirtide 55 unresectable HCC 55 primary patency 55 elevated transaminases 55 histologic subtype 55 IOP lowering 55 receiving golimumab 55 chemotherapeutic regimen 55 prior relapsers 55 mcg doses 55 pegfilgrastim 55 galiximab 55 estramustine 55 log# 54 noninferiority 54 ritonavir Norvir 54 pmol L 54 composite endpoint 54 PREZISTA ritonavir 54 carboplatin paclitaxel 54 Phase Ib study 54 gemcitabine cisplatin 54 curative resection 54 REYATAZ r arm 54 Score DAS# 54 Phase 2a trial 54 serum clusterin levels 54 sitaxsentan 54 hematologic toxicity 54 daunorubicin 54 pretreatment serum 54 phase Ib 54 atheroma volume 54 CSBM 54 mg dose 54 baminercept 54 MVax R 54 Aloxi injection 54 hypophosphatemia 54 thrombocytopenic 54 darunavir 54 PAOD 54 methotrexate monotherapy 54 BR.# 54 alfa 2a 54 CLARITY study 54 hypokalemia 54 seminal vesicle invasion 54 total thyroidectomy 54 pimecrolimus cream 54 alanine aminotransferase 54 torezolid 54 INCB# [001] 54 efficacy evaluable 54 viral titer 54 poor metabolizers 54 EOquin TM 54 FOLPI 54 CIN2 + 54 Omacetaxine 54 leukocyte count 54 DLTs 54 atazanavir sulfate 54 aPTT 54 nondiabetic patients 54 CD4 + cell 54 eosinophilic asthma 54 randomized Phase IIb 54 ULORIC 54 neoadjuvant 54 adjunctive placebo 54 PEG Intron 54 salmeterol fluticasone 54 recurrent venous thromboembolism 54 sUA levels 54 RAEB 54 aged ≥ 54 incontinence episodes 54 F FDG PET 54 titrated glipizide 54 PegIFN RBV 54 HCV genotype 54 dasatinib Sprycel 54 elevated ALT 54 3mg/kg 54 goserelin 54 baseline A1C 54 Kaplan Meier 54 SCr 54 Folfox 54 chronic HCV genotype 54 lymphocyte count 54 Partial Response 54 virologic responses 54 REYATAZ ® 54 Scale EDSS score 54 estimated GFR 54 PREZISTA r arm 54 epithelial tumors 54 underwent liver transplantation 54 HAM D# scores 54 mg/m2 cohort 54 #mg dose [002] 54 PROMACTA 54 CsA 54 sUA 54 imipenem 54 Timed Walk 54 PRADAXA #mg 54 Naive Patients 54 acute leukemias 54 oral rivaroxaban 54 aspartate aminotransferase 54 IFN α 54 anemia neutropenia 54 T1a 54 refractory MCL 54 ng dL 54 systolic dysfunction 54 secondary efficacy endpoint 54 dose escalation phase 54 continuous intravenous infusion 54 pancreatic neuroendocrine tumors 54 Kinoid 54 dalteparin 54 postoperative chemotherapy 54 GOUT 54 completely resected 54 moderate renal impairment 54 transplant ASCT 54 docetaxel Taxotere ® 54 neutrophil counts 54 serum cortisol 54 AZT zidovudine Retrovir 54 nodular partial response 54 relapsed CLL 54 Sprycel dasatinib 54 ZACTIMA 54 PreCISe study 54 hepatectomy 54 spontaneous bowel movements 54 FOLFOX4 54 Scale EDSS 54 HGPIN 54 Kaplan Meier method 54 randomized blinded 54 relapsed refractory 54 antiretroviral naive 54 biologic therapy 54 concomitant medications 54 #mg QD [001] 54 clinically evaluable population 54 prostate cancer CaP 54 MGUS 54 IV NSCLC 54 paclitaxel carboplatin 54 #mg BID [002] 54 investigational protease inhibitor 54 ACZ# 54 insulin detemir 54 hip BMD 54 DMARD 54 trabedersen 54 albumin excretion rate 54 ‰ ¥ 54 Natalizumab 54 viral kinetic 54 adenoma recurrence 54 interferon alfa 54 brentuximab vedotin SGN 54 MMSE score 54 darunavir ritonavir 54 underwent CABG 54 anemia hemoglobin 54 Cloretazine 54 mg BID dose 54 pegylated interferon alfa 2a 54 postmenopausal osteoporotic women 54 mcg kg REBETOL 54 ponatinib 54 prospectively randomized 54 dacarbazine 54 A1c levels 54 achieved PASI 54 grade cervical intraepithelial 54 lispro 54 administered subcutaneously 54 microgram kg 54 Sustained virologic response 53 FAME Study 53 dose melphalan 53 follicular NHL 53 INCB# [003] 53 lopinavir r 53 Actilon 53 Jevtana 53 μg kg 53 HbA1C levels 53 MoxDuo TM IR 53 Gleevec resistant 53 non splenectomized 53 NATRECOR R 53 CYT# potent vascular disrupting 53 ToGA 53 alemtuzumab treated 53 Durezol 53 KRAS status 53 Abbott HUMIRA 53 PANVAC VF 53 REYATAZ r 53 elevated troponin 53 castration resistant prostate cancer 53 #.#ng/ml 53 asthma exacerbation 53 NSTE ACS 53 pegylated alpha interferon 53 lymphoid malignancies 53 DermaVir Patch 53 Partial Responses 53 comparator arm 53 mcg dose 53 paraprotein 53 alteplase 53 RECIST Response Evaluation Criteria 53 HIV HCV coinfected 53 peginterferon alfa 53 adefovir 53 platelet reactivity 53 ACR# ACR# 53 serum phosphorus 53 lymphocyte counts 53 atrioventricular block 53 Pegylated Liposomal Doxorubicin 53 evaluable 53 adriamycin 53 PEGylated anti 53 amprenavir 53 oral diclofenac 53 pegylated interferon 53 Kaplan Meier analysis 53 achieved sustained virologic 53 combination antiretroviral therapy 53 Solid Tumours 53 sipuleucel T 53 non squamous NSCLC 53 assessing T DM1 53 Enzastaurin 53 locoregional recurrence 53 azacytidine 53 nicardipine 53 CCR5 tropic 53 Expanded Disability Status 53 p = NS 53 Pemetrexed 53 multiple myeloma MM 53 recurrent NSCLC 53 graft dysfunction 53 tolterodine ER 53 randomized multicenter 53 recanalization 53 albumin excretion 53 morphometric vertebral fractures 53 baseline FEV 53 fluvastatin 53 prostate carcinoma 53 linezolid 53 Aptivus ® 53 boosted protease inhibitor 53 antibody titers 53 glycosylated hemoglobin HbA1c 53 nitazoxanide 53 HAMD 53 cells μL 53 parasitemia 53 dose titration 53 PSMA ADC 53 placebo controlled clinical 53 COPAXONE R 53 Virulizin ® 53 â ‰ ¥ 53 genotype 1a 53 CLORETAZINE TM VNP#M 53 gefitinib Iressa 53 Free Survival PFS 53 bcr abl 53 Campath alemtuzumab 53 sunitinib malate 53 pentoxifylline 53 alicaforsen enema 53 PsA 53 Ophena TM 53 rituximab refractory 53 EGFR mutation positive 53 observational cohort study 53 nucleoside analog 53 divalproex sodium 53 Pharmacokinetics PK 53 docetaxel prednisone 53 rindopepimut 53 monoinfected 53 valopicitabine 53 adjuvant tamoxifen 53 metastatic renal cell 53 thymoma 53 fluticasone salmeterol 53 plus ribavirin 53 AGILECT ® 53 confirmed CCyR 53 LHRH agonist 53 ABSORB trial 53 TURBT 53 oocytes retrieved 53 eplerenone 53 PRECiSE 53 CrCl 53 NNRTI resistance 53 achieved statistical significance 53 zonisamide SR 53 abiraterone acetate 53 transaminase 53 relapsers 53 FDG PET scans 53 NYHA functional class 53 multicenter multinational 53 ARCOXIA 53 taxane chemotherapy 53 dose dose escalation 53 #mg/m# [002] 53 REMINYL ® 53 μg doses 53 subcutaneous doses 53 GERD symptom 53 visceral metastases 53 Cimzia ® certolizumab pegol 53 double blinded placebo 53 tumor recurrence 53 genital ulcers 53 absolute lymphocyte 53 BRIM3 53 postprocedure 53 chronic HCV infection 53 multicenter randomized placebo controlled 53 Gastrointestinal Stromal Tumors 53 mCi 53 low dose ritonavir 53 T1DM 53 mg subcutaneously 53 multicenter randomized controlled 53 bicifadine 53 mg eq 53 mCi m 2 53 atazanavir Reyataz 53 PROSTVAC VF 53 QTc prolongation 53 Severity Index PASI 53 SSc patients 53 mycophenolate mofetil 53 hypogonadal men 53 MACUGEN 53 rituximab monotherapy 53 HCV genotypes 53 vinorelbine 53 iPTH 53 EURIDIS 53 efficacy endpoint 53 RE LY ® 53 ZD# [001] 53 severe rotavirus gastroenteritis 53 immunosuppressive regimen 53 thyroid carcinoma 53 relapsed Hodgkin lymphoma 53 alvespimycin 53 hepatic resection 53 Phase #/#a trial 53 pancreatic adenocarcinoma 53 XIENCE V demonstrated 53 Telaprevir 53 overt nephropathy 53 reinfarction 53 clinically meaningful improvements 53 mg kg cohorts 53 pain palliation 53 prospective multicenter randomized 53 squamous histology 53 CK # plasma concentrations 53 EBRT 53 Solid Tumors 53 CCX# 53 ECOG PS 53 secondary endpoint 53 HIV uninfected 53 Histologic 53 rilpivirine 53 saline placebo 53 #μg [002] 53 lactate dehydrogenase LDH 53 nonresponders 53 HCV replicon 53 imiquimod cream 53 Taxotere ® 53 cells uL 52 pancreatic carcinoma 52 Non inferiority 52 Plenaxis TM 52 % CI #.#-#.# [007] 52 treatment naļve 52 nevirapine Viramune 52 mg/m2 52 Phase IIb clinical trials 52 bleeding pallor 52 MS relapses 52 hematological parameters 52 HER2 overexpression 52 death reinfarction 52 Tipranavir 52 Corlux 52 intraperitoneally 52 T1c 52 spirometric 52 liver metastases 52 Fludara 52 sorafenib Nexavar 52 febrile neutropenia 52 GAMMAGARD 52 oral ibandronate 52 tolvaptan 52 R0 resection 52 pertuzumab 52 microg 52 perioperatively 52 serum CRP 52 operable breast cancer 52 APTIVUS 52 Phase III randomized controlled 52 RhuDex ® 52 differentiated thyroid 52 NHANES III 52 CD# upregulation 52 mg RDEA# 52 prodromal symptoms 52 cobicistat 52 Postoperative complications 52 zidovudine lamivudine 52 dosing intervals 52 ISENTRESS 52 ≥ 52 minimally symptomatic 52 calculated creatinine clearance 52 clinical pharmacology studies 52 urinary N telopeptide 52 ADHF 52 retrospective observational study 52 EDEMA3 52 prospectively stratified 52 papillary renal cell carcinoma 52 mutated KRAS 52 DOXIL 52 plasma pharmacokinetics 52 Femara letrozole 52 ascending doses 52 tenofovir emtricitabine 52 cobiprostone